CompletedNot Applicable

Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas

128 participantsStarted 2010-07-15

Plain-language summary

This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.

Who can participate

Age range2 Weeks – 54 Weeks

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * IHs diagnosed by medical history and physical examination * no previous treatment with other medications Exclusion Criteria: * a history or risk of asthma, reactive airway disease, impaired renal or liver function, heart defects or arrhythmia, hypotension and hypersensitivity to propranolol * Infants who did not adhere to the treatments or attend follow-up visits * Infants with other known risk factors for developmental delay or growth restriction, such as prematurity, small for gestational age, or other major congenital malformations, were also excluded * No other treatment was used during the oral propranolol course

What they're measuring

Change on the height of the patients

Timeframe: at the beginning of the treatment, at the end of treatment and 2 years after the treatment

Change on the weight of the patients

Timeframe: at the beginning of the treatment, at the end of treatment and 2 years after the treatment

Trial details

NCT IDNCT04651049

SponsorQilu Hospital of Shandong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-12-15

View on ClinicalTrials.gov More Infantile Haemangiomas trials